Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus

A randomized, placebo-controlled study

Mark S. Kipnes, Arthur Krosnick, Marc S. Rendell, John W. Egan, Annette L. Mathisen, Roberta L. Schneider

Research output: Contribution to journalArticle

246 Citations (Scopus)

Abstract

PURPOSE: To evaluate the efficacy and tolerability of pioglitazone in combination with a sulfonylurea in the treatment of type 2 diabetes mellitus. SUBJECTS AND METHODS: This 16-week, double-blind study included patients on a stable regimen of a sulfonylurea for ≥30 days and with a glycosylated hemoglobin (HbA1C) level ≥8.0%. Patients were randomly assigned to receive once daily pioglitazone 15 mg (n = 184), pioglitazone 30 mg (n = 189), or placebo plus sulfonylurea (n = 187). RESULTS: Patients receiving pioglitazone + sulfonylurea had significant (P 1C and fasting plasma glucose levels compared with patients treated with placebo + sulfonylurea. As compared with placebo, HbA1C decreased by 0.9% (95% confidence interval [CI]: 0.06% to 1.2%) with pioglitazone 15 mg and 1.3% (CI: 1% to 1.6%) with 30 mg pioglitazone; fasting plasma glucose levels decreased by 39 mg/dL (95% CI: 27 to 52 mg/dL) with pioglitazone 15 mg and by 58 mg/dL (95% CI: 46-70 mg/dL) with 30 mg pioglitazone. Both pioglitazone + sulfonylurea groups had significant (P 1C and fasting plasma glucose levels with beneficial effects on serum triglyceride and HDL-cholesterol levels.

Original languageEnglish
Pages (from-to)10-17
Number of pages8
JournalAmerican Journal of Medicine
Volume111
Issue number1
DOIs
StatePublished - 2001

Fingerprint

pioglitazone
Type 2 Diabetes Mellitus
Placebos
Confidence Intervals
Fasting
Therapeutics
Glucose
Glycosylated Hemoglobin A

All Science Journal Classification (ASJC) codes

  • Nursing(all)

Cite this

Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus : A randomized, placebo-controlled study. / Kipnes, Mark S.; Krosnick, Arthur; Rendell, Marc S.; Egan, John W.; Mathisen, Annette L.; Schneider, Roberta L.

In: American Journal of Medicine, Vol. 111, No. 1, 2001, p. 10-17.

Research output: Contribution to journalArticle

Kipnes, Mark S. ; Krosnick, Arthur ; Rendell, Marc S. ; Egan, John W. ; Mathisen, Annette L. ; Schneider, Roberta L. / Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus : A randomized, placebo-controlled study. In: American Journal of Medicine. 2001 ; Vol. 111, No. 1. pp. 10-17.
@article{eb6645f498474a70a2236a39d11cb43c,
title = "Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, placebo-controlled study",
abstract = "PURPOSE: To evaluate the efficacy and tolerability of pioglitazone in combination with a sulfonylurea in the treatment of type 2 diabetes mellitus. SUBJECTS AND METHODS: This 16-week, double-blind study included patients on a stable regimen of a sulfonylurea for ≥30 days and with a glycosylated hemoglobin (HbA1C) level ≥8.0{\%}. Patients were randomly assigned to receive once daily pioglitazone 15 mg (n = 184), pioglitazone 30 mg (n = 189), or placebo plus sulfonylurea (n = 187). RESULTS: Patients receiving pioglitazone + sulfonylurea had significant (P 1C and fasting plasma glucose levels compared with patients treated with placebo + sulfonylurea. As compared with placebo, HbA1C decreased by 0.9{\%} (95{\%} confidence interval [CI]: 0.06{\%} to 1.2{\%}) with pioglitazone 15 mg and 1.3{\%} (CI: 1{\%} to 1.6{\%}) with 30 mg pioglitazone; fasting plasma glucose levels decreased by 39 mg/dL (95{\%} CI: 27 to 52 mg/dL) with pioglitazone 15 mg and by 58 mg/dL (95{\%} CI: 46-70 mg/dL) with 30 mg pioglitazone. Both pioglitazone + sulfonylurea groups had significant (P 1C and fasting plasma glucose levels with beneficial effects on serum triglyceride and HDL-cholesterol levels.",
author = "Kipnes, {Mark S.} and Arthur Krosnick and Rendell, {Marc S.} and Egan, {John W.} and Mathisen, {Annette L.} and Schneider, {Roberta L.}",
year = "2001",
doi = "10.1016/S0002-9343(01)00713-6",
language = "English",
volume = "111",
pages = "10--17",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus

T2 - A randomized, placebo-controlled study

AU - Kipnes, Mark S.

AU - Krosnick, Arthur

AU - Rendell, Marc S.

AU - Egan, John W.

AU - Mathisen, Annette L.

AU - Schneider, Roberta L.

PY - 2001

Y1 - 2001

N2 - PURPOSE: To evaluate the efficacy and tolerability of pioglitazone in combination with a sulfonylurea in the treatment of type 2 diabetes mellitus. SUBJECTS AND METHODS: This 16-week, double-blind study included patients on a stable regimen of a sulfonylurea for ≥30 days and with a glycosylated hemoglobin (HbA1C) level ≥8.0%. Patients were randomly assigned to receive once daily pioglitazone 15 mg (n = 184), pioglitazone 30 mg (n = 189), or placebo plus sulfonylurea (n = 187). RESULTS: Patients receiving pioglitazone + sulfonylurea had significant (P 1C and fasting plasma glucose levels compared with patients treated with placebo + sulfonylurea. As compared with placebo, HbA1C decreased by 0.9% (95% confidence interval [CI]: 0.06% to 1.2%) with pioglitazone 15 mg and 1.3% (CI: 1% to 1.6%) with 30 mg pioglitazone; fasting plasma glucose levels decreased by 39 mg/dL (95% CI: 27 to 52 mg/dL) with pioglitazone 15 mg and by 58 mg/dL (95% CI: 46-70 mg/dL) with 30 mg pioglitazone. Both pioglitazone + sulfonylurea groups had significant (P 1C and fasting plasma glucose levels with beneficial effects on serum triglyceride and HDL-cholesterol levels.

AB - PURPOSE: To evaluate the efficacy and tolerability of pioglitazone in combination with a sulfonylurea in the treatment of type 2 diabetes mellitus. SUBJECTS AND METHODS: This 16-week, double-blind study included patients on a stable regimen of a sulfonylurea for ≥30 days and with a glycosylated hemoglobin (HbA1C) level ≥8.0%. Patients were randomly assigned to receive once daily pioglitazone 15 mg (n = 184), pioglitazone 30 mg (n = 189), or placebo plus sulfonylurea (n = 187). RESULTS: Patients receiving pioglitazone + sulfonylurea had significant (P 1C and fasting plasma glucose levels compared with patients treated with placebo + sulfonylurea. As compared with placebo, HbA1C decreased by 0.9% (95% confidence interval [CI]: 0.06% to 1.2%) with pioglitazone 15 mg and 1.3% (CI: 1% to 1.6%) with 30 mg pioglitazone; fasting plasma glucose levels decreased by 39 mg/dL (95% CI: 27 to 52 mg/dL) with pioglitazone 15 mg and by 58 mg/dL (95% CI: 46-70 mg/dL) with 30 mg pioglitazone. Both pioglitazone + sulfonylurea groups had significant (P 1C and fasting plasma glucose levels with beneficial effects on serum triglyceride and HDL-cholesterol levels.

UR - http://www.scopus.com/inward/record.url?scp=0034933056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034933056&partnerID=8YFLogxK

U2 - 10.1016/S0002-9343(01)00713-6

DO - 10.1016/S0002-9343(01)00713-6

M3 - Article

VL - 111

SP - 10

EP - 17

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 1

ER -